Ligilactobacillus salivarius CNCM I-4866, a potential probiotic candidate, shows anti-inflammatory properties in vitro and in vivo

Celia Carbonne; Sead Chadi; Camille Kropp; Lise Molimard; Florian Chain; Philippe Langella; Rebeca Martin

doi:10.3389/fmicb.2023.1270974

Ligilactobacillus salivarius CNCM I-4866, a potential probiotic candidate, shows anti-inflammatory properties in vitro and in vivo

Front Microbiol. 2023 Nov 29:14:1270974. doi: 10.3389/fmicb.2023.1270974. eCollection 2023.

Authors

Celia Carbonne¹, Sead Chadi¹, Camille Kropp¹, Lise Molimard¹, Florian Chain¹, Philippe Langella¹, Rebeca Martin¹

Affiliation

¹ Micalis Institute, AgroParisTech, INRAE, Université Paris-Saclay, Jouy-en-Josas, France.

Abstract

Introduction: The aim of this work was to characterize a new strain of Ligilactobacillus salivarius (CNCM I-4866) (CNCM I-4866) to address its potential as probiotic with a special focus on intestinal inflammation. Potential anti-inflammatory abilities of this strain were evaluated through in vivo and in vitro experiments.

Methods: Firstly, the strain was tested in a murine acute inflammation colitis model induced by DNBS. In vitro characterization was then performed with diverse tests: modulation capability of intestinal permeability; study of the impact on immunity profile through cytokines dosage; capacity to inhibit pathogens and adhere to intestinal cells lines. Production of metabolites, antibiotic resistance and survival to gastro-intestinal tract conditions were also tested.

Results: In vitro assay has shown a reduction of colonic damage and markers of inflammation after treatment with CNCM I-4866. Transcriptomic analysis performed on colons showed the capacity of the strain to down-regulate pro-inflammatory cytokines. L. salivarius CNCM I-4866 exerted anti-inflammatory profile by reducing IL-8 production by TNF-α stimulated cell and modulated cytokines profile on peripheral blood mononuclear cells (PBMC). It protected intestinal integrity by increasing trans-epithelial electrical resistance (TEER) on Caco-2 TNF-α inflamed cells. Additionally, L. salivarius CNCM I-4866 displayed inhibition capacity on several intestinal pathogens and adhered to eukaryotic cells. Regarding safety and technical concerns, CNCM I-4866 was highly resistant to 0.3% of bile salts and produced mainly L-lactate. Finally, strain genomic characterization allowed us to confirm safety aspect of our strain, with no antibiotic gene resistance found.

Discussion: Taken together, these results indicate that L. salivarius CNCM I-4866 could be a good probiotic candidate for intestinal inflammation, especially with its steady anti-inflammatory profile.

Keywords: DNBS inflammation; Ligilactobacillus salivarius; anti-inflammatory; in vitro; probiotic.

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This project was funded by the SORBIAL company. The SORBIAL company played no role in data collection and interpretation.